NTLA·Nasdaq·US
Intellia Therapeutics
Intellia Therapeutics is a biopharmaceutical company that uses CRISPR gene editing and other core technologies to develop and commercialize potentially curative treatments for severe diseases, including lonvo-z for hereditary angioedema and nex-z for transthyretin amyloidosis, which are the first in vivo genome editing product candidates to reach Phase 3 development.
Source: SEC 10-K Feb 26, 2026
Recent Activity
Updated Sep 24, 2026
–Intellia Therapeutics is preparing for a potential launch of lonvo-z, its hereditary angioedema treatment, as the drug's PDUFA date approaches.
–The company designed its HAE program as an all-comers study that excludes pediatric patients under 16 but does not restrict enrollment based on prior therapy.
–Intellia is also advancing its TTR (transthyretin) study.
Past updates are part of the Pro plan.
Thematic Position
Relationship Groups
Relationship details are part of the Pro plan.
Recent Discoveries
Recent discoveries are part of the Pro plan.